Evidence map›Paper›PMID 40974077›Full record

ArticleJournal of molecular cell biology2026

Automating classification of treatment responses to combined targeted therapy and immunotherapy in HCC.

Bing Quan, Mingrong Dai, Peiling Zhang, Shiping Chen, Jialiang Cai, Yujie Shao, Pengju Xu, Peizhao Li, Lei Yu

Abstract read
In one paragraph

Article in Journal of molecular cell biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Bing QuanLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Mingrong DaiLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Peiling ZhangLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Shiping ChenLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Jialiang CaiLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Yujie ShaoLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Pengju XuDepartment of Radiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Peizhao LiDepartment of Information and Intelligence Development, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Lei YuLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China.ORCID 0009-0002-4341-2059

Funding

National Science Foundation for Young Scientists of China 81301821
6 · The paper itself

Abstract

Tyrosine kinase inhibitor (TKI) combined with immunotherapy regimens are now widely used for treating advanced hepatocellular carcinoma (HCC), but their clinical efficacy is limited to a subset of patients. Considering that the vast majority of advanced HCC patients lose the opportunity for liver resection and thus cannot provide tumor tissue samples, we leveraged the clinical and image data to construct a multimodal convolutional neural network (CNN)-Transformer model for predicting and analyzing tumor response to TKI-immunotherapy. We employed an automatic liver tumor segmentation system, based on a two-stage 3D U-Net framework, to delineate lesions by first segmenting the liver parenchyma and then precisely localizing the tumor. This approach effectively addresses the variability in clinical data and significantly reduces bias introduced by manual intervention. Next, we developed a clinical model using only pretreatment clinical information, a CNN model using only pretreatment magnetic resonance imaging data, and an advanced multimodal CNN-Transformer model fusing both imaging and clinical parameters from a training cohort (n = 181) and then compared their predictive performances in an independent cohort (n = 30). In the validation cohort, the area under the curve (95% confidence interval) values were 0.720 (0.710-0.731), 0.695 (0.683-0.707), and 0.785 (0.760-0.810), respectively, indicating that the multimodal model significantly outperformed the single-modality baseline models across validations. Finally, single-nucleus sequencing with the surgical tumor specimens reveals tumor ecosystem diversity associated with treatment response, providing a preliminary biological validation for the prediction model. In summary, this multimodal model effectively integrates imaging and clinical features of HCC patients, has a superior performance in predicting tumor response to TKI-immunotherapy, and provides a reliable tool for optimizing personalized treatment strategies.

Indexed as

Carcinoma, HepatocellularImmunotherapyLiver NeoplasmsMolecular Targeted TherapyAgedFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedNeural Networks, ComputerProtein Kinase InhibitorsTreatment OutcomeProtein Kinase Inhibitorsconvolutional neural networkshepatocellular carcinomamultimodal modeltumor response

Identifiers

PMID40974077
PMCPMC12901565

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.